Trial shows stapokibart helps elderly bullous pemphigoid patients

Researchers studied a new drug called stapokibart in 15 elderly patients with moderate-to-severe bullous pemphigoid, a rare skin condition. The patients received stapokibart along with standard topical or systemic glucocorticoid therapy for 24 weeks. The study found that all 15 patients achieved disease control within an average of about 10 days. By the end of the treatment period, key measures of skin disease, quality of life, itch, and a related antibody level were all significantly reduced from baseline. The treatment was reported as well-tolerated, but the study did not provide specific details on side effects or adverse events. This was a small, single-center, retrospective case series without a control group, so the results are preliminary. The main reason to be cautious is the study's design and size, which limit how confidently we can apply these findings. The realistic takeaway is that stapokibart may be a helpful add-on therapy for this condition, but much larger, controlled trials are needed to confirm its long-term benefits and safety.